Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

I think 3 years is a stretch at this rate of development. Vigabatrin will hopefully launch within the next 3-4 months, which provides little benefit to 2022 rev as it ramps up. Elite has no idea what it’s doing with Doxy at this point. Rev growth can be bought with Adderall rights from Mikah, but that will come at a cost, but growth is growth. I think the pipeline needs to move much faster to grow over 3x in 3 years. Even if an ADT is submitted Q1/Q2 next year, there would be no financial benefit next year as it takes 10+ months for FDA to review. Then layer on marketing/distributor partnership and then launching. Perhaps 3 years is possible to hit 100M, which would be great to see, but I think it’s unrealistic. Aug earnings call will give us some insight into organic growth over last year, which I expect to be slightly up, but far less than the 27% growth we experienced for FY22.